Literature DB >> 19659609

Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.

Kaku Goto1, Koichi Watashi, Daisuke Inoue, Makoto Hijikata, Kunitada Shimotohno.   

Abstract

We have so far reported that an immunosuppressant cyclosporin A (CsA), a well-known cyclophilin (CyP) inhibitor (CPI), strongly suppressed hepatitis C virus (HCV) replication in cell culture, and that CyPB was a cellular cofactor for viral replication. To further investigate antiviral mechanisms of CPI, we here developed cells carrying CsA-resistant HCV replicons, by culturing the HCV subgenomic replicon cells for 4 weeks in the presence of CsA with G418. Transfection of total RNA from the isolated CsA-resistant cells to naïve Huh7 cells conferred CsA resistance, suggesting that the replicon RNA itself was responsible for the resistant phenotype. Of the identified amino acid mutations, D320E in NS5A conferred the CsA resistance. The replicon carrying the D320E mutation was sensitive to interferon-alpha, but was resistant to CsA and other CPIs including NIM811 and sanglifehrin A. Knockdown of individual CyP subtypes revealed CyP40, in addition to CyPA and CyPB, contributed to viral replication, and CsA-resistant replicons acquired independence from CyPA for efficient replication. These data provide important evidence on the mechanisms underlying the regulation of HCV replication by CyP and for designing novel and specific anti-HCV strategies with CPIs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19659609     DOI: 10.1111/j.1349-7006.2009.01263.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  25 in total

1.  Cyclosporin A inhibits the replication of diverse coronaviruses.

Authors:  Adriaan H de Wilde; Jessika C Zevenhoven-Dobbe; Yvonne van der Meer; Volker Thiel; Krishna Narayanan; Shinji Makino; Eric J Snijder; Martijn J van Hemert
Journal:  J Gen Virol       Date:  2011-07-13       Impact factor: 3.891

Review 2.  Anti-HCV drugs in the pipeline.

Authors:  Priscilla L Yang; Min Gao; Kai Lin; Qingsong Liu; Valerie A Villareal
Journal:  Curr Opin Virol       Date:  2011-11-13       Impact factor: 7.090

Review 3.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

4.  Identification of cyclophilin-40-interacting proteins reveals potential cellular function of cyclophilin-40.

Authors:  Miki Susanto Park; Feixia Chu; Jinghang Xie; Yu Wang; Pompeya Bhattacharya; William K Chan
Journal:  Anal Biochem       Date:  2010-12-10       Impact factor: 3.365

5.  Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.

Authors:  Matthew A Gregory; Michael Bobardt; Susan Obeid; Udayan Chatterji; Nigel J Coates; Teresa Foster; Philippe Gallay; Pieter Leyssen; Steven J Moss; Johan Neyts; Mohammad Nur-e-Alam; Jan Paeshuyse; Mahmood Piraee; Dipen Suthar; Tony Warneck; Ming-Qiang Zhang; Barrie Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

6.  New antiviral therapies for chronic hepatitis C.

Authors:  Tatsuo Kanda; Fumio Imazeki; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2010-08-19       Impact factor: 6.047

7.  DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Authors:  Lotte Coelmont; Xavier Hanoulle; Udayan Chatterji; Carola Berger; Joke Snoeck; Michael Bobardt; Precious Lim; Inge Vliegen; Jan Paeshuyse; Grégoire Vuagniaux; Anne-Mieke Vandamme; Ralf Bartenschlager; Philippe Gallay; Guy Lippens; Johan Neyts
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

8.  A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.

Authors:  Feng Yang; Jason M Robotham; Henry Grise; Stephen Frausto; Vanesa Madan; Margarita Zayas; Ralf Bartenschlager; Margaret Robinson; Andrew E Greenstein; Anita Nag; Timothy M Logan; Ewa Bienkiewicz; Hengli Tang
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

9.  Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.

Authors:  Jose A Garcia-Rivera; Michael Bobardt; Udayan Chatterji; Sam Hopkins; Matthew A Gregory; Barrie Wilkinson; Kai Lin; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

10.  The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

Authors:  Sam Hopkins; Michael Bobardt; Udayan Chatterji; Jose A Garcia-Rivera; Precious Lim; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.